GAPVAC-101: personalized vaccines for newly-diagnosed glioblastoma
Drugs with low response rates - should they always be offered to patients?
Cabozantinib for advanced renal cell carcinoma: the METEOR and CABOSUN trials
Understanding resistance to combined BRAF and MEK inhibiton in melanoma and the significance of CDK4
Trial results of vemurafenib, cobimetinib and LDH as a predictive marker in BRAF-mutated melanoma